White label ELPA - ClinicalTrials.eu

Study of Lutetium-177-PSMA treatment for patients with advanced clear cell kidney cancer who had progression after first or second line therapy

Recruiting

2 1 1 1
Investigated Diseases:
- Clear cell renal cell carcinoma
Investigated Drugs:
- Lutetium (177Lu) Vipivotide Tetraxetan
Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Recruiting

3 1
Investigated Drugs:
- IBUZATRELVIR
- Remdesivir
+3
Study of BMS-986368 to treat muscle stiffness in people with Multiple Sclerosis

Recruiting

2 1
Study of carboplatin, paclitaxel, and tislelizumab treatment in patients with resectable locally advanced oral cavity squamous cell carcinoma

Recruiting

2 1 1 1
Investigated Drugs:
Study of Remternetug for Prevention of Disease Progression in People at Risk for or With Early Onset Inherited Alzheimer’s Disease

Recruiting

4 1
Investigated Diseases:
- Dementia Alzheimer’s type
Investigated Drugs:
- LY3372993
- N-Methyl-2-(4′-Methylaminophenyl)-6-Hydroxybenzothiazole
Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Recruiting

3 1 1 1
Investigated Diseases:
- Colorectal cancer metastatic
- K-ras gene mutation
Investigated Drugs:
+3
Comparing two forms of mupirocin (gel and ointment) for treating impetigo in children: a study of different dosing schedules

Recruiting

3 1 1 1
Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

Recruiting

2 1 1 1
Investigated Drugs:
- Mirvetuximab Soravtansine
- Prednisolone Acetate
Study of ABBV-453 alone or with drug combination for adults with multiple myeloma: evaluation of safety and effectiveness

Recruiting

1 1 1 1
Investigated Diseases:
- Plasma cell myeloma
Investigated Drugs:
+1
Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Recruiting

3 1 1 1
Investigated Drugs:
+6

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies